Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Tumor-Agnostic 1Thoracic 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Solid Tumor, Adult 1Advanced Solid Tumors 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × peposertib × Other solid neoplasm × Clear all
NCT02516813 2024-10-15

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

EMD Serono

Phase 1 Completed
52 enrolled 43 charts
Other solid neoplasm

Advanced Solid Tumors

NCT05868174 2024-05-01

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 1 Recruiting
36 enrolled
GenitourinaryOther solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡